中文
EN
News Center
News Center
Review, Align, and Move Forward — Viwit Successfully Holds 2026 Mid-Year Business Meeting
Author：
VIWIT
Release Time：
2026-07-19
On July 18, Viwit held its 2026 Mid-Year Business Review Meeting to assess first-half performance, identify gaps and challenges, and define priorities for the second half of the year. President Dr. Keene Wei delivered the strategic address. Executive Vice President Guo Xinhai chaired the meeting, joined by Vice President Zhang Hao and leaders from the company’s profit centers and business units.
Data-Driven Review: Recognizing Progress and Addressing Gaps
Business unit leaders presented detailed updates covering operating performance, project execution, market development, and team building. The reviews were grounded in objective data and real-world examples, highlighting both achievements and areas requiring improvement. Analyses of market conditions, execution, and cross-functional collaboration provided clear direction for operational improvement and management optimization in the second half of the year.
Executive Vice President Guo Xinhai reviewed each business unit’s report, recognized the teams’ efforts and progress during the first half, and set clear expectations for addressing performance gaps. He emphasized disciplined execution and sustained focus on annual objectives.
Strategic Direction and Innovation for Future Growth
During the strategy session, Dr. Keene Wei outlined priorities for the second half of 2026 and the period ahead. He noted that the company had made meaningful progress in project execution, market development, and team building, while additional work remained to achieve full-year objectives. Against the backdrop of significant change across the pharmaceutical and healthcare industry, he called on teams to maintain confidence, strengthen execution, and stay focused on annual goals.
Dr. Wei outlined six strategic priorities for the second half of the year:
1 | Focus the Portfolio and Strengthen the Foundation
Concentrate resources on core products, including VivaQuit, while continuing to improve cost efficiency and strengthen the foundation for sustainable operations.
2 | Lead with Innovation and Advance at the Frontier
Build an innovation-focused product pipeline and accelerate differentiated, higher-value innovation.
3 | Apply Scientific Marketing and Strengthen the Brand
Advance evidence-based marketing and brand development, deepen the company’s presence in China, and plan for international expansion.
4 | Build a Strong Talent Pipeline and Improve Management Effectiveness
Strengthen talent development and leadership succession while building a diverse, global, high-performing team.
5 | Strengthen Culture and Put the Mission into Practice
Bring the mission “Innovation for a Better Life” into day-to-day decision-making and execution.
6 | Strengthen Risk Management and Organizational Resilience
Maintain rigorous QEHS standards, actively strengthen organizational capability, and proactively manage operational and regulatory risks.
Aligned for the Next Phase of Growth
The mid-year meeting served both as a disciplined review of first-half performance and as a forward-looking plan for the remainder of the year. With a shared commitment to “Innovation for a Better Life,” Viwit will continue executing against its annual objectives, advancing high-quality growth, and contributing to innovation across the pharmaceutical and healthcare industry.
Innovation sets the course; execution drives progress. Viwit is moving forward into the second half of the year.